Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for neuroblastoma, susceptibility to, 4 has been reported in the published literature.
No clinical trials have been registered for neuroblastoma, susceptibility to, 4.
20 publications have been identified in PubMed for neuroblastoma, susceptibility to, 4. Kisho has analyzed 5 by research type. Research spans Basic Science / Preclinical (40%), Diagnostic / Biomarker (20%), and Review / Meta-Analysis (20%).
Kim EY (2025). [PMID: 40835619](https://pubmed.ncbi.nlm.nih.gov/40835619/). *Sci Rep*. [Epidemiology / Natural History]
Chen Y (2025). [PMID: 40121577](https://pubmed.ncbi.nlm.nih.gov/40121577/). *Discov Oncol*. [Diagnostic / Biomarker]
Ferdous J (2025). [PMID: 39993732](https://pubmed.ncbi.nlm.nih.gov/39993732/). *J Vet Med Sci*. [Basic Science / Preclinical]
Konishi K (2024). [PMID: 39089332](https://pubmed.ncbi.nlm.nih.gov/39089332/). *Antiviral Res*. [Basic Science / Preclinical]
Kamihara J (2024). [PMID: 38860978](https://pubmed.ncbi.nlm.nih.gov/38860978/). *Clin Cancer Res*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:55 PM UTC
Online Mendelian Inheritance in Man